Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff
Johnson & Johnson has struck a $3.05 billion cash deal to acquire Halda Therapeutics, a privately held cancer-drug developer based in New Haven, Connecticut, in one of 2025’s biggest oncology takeovers so far. Reuters+1 The move deepens J&J’s bet on cancer medicines just as sales of its long‑time blockbuster psoriasis drug Stelara are being hit hard by a wave of cheaper biosimilar rivals. Yahoo Finance+1 Key points Inside Johnson & Johnson’s Halda Therapeutics takeover J&J said on Monday that it will acquire Halda Therapeutics for $3.05 billion in cash, adding a new set of precision oncology assets to its Innovative